SFSIG
RIGL icon

San Francisco Sentry Investment Group’s Rigel Pharmaceuticals RIGL Stock Holding History

San Francisco Sentry Investment Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-30
Closed -$1K – 852
2018
Q1 		$1K Hold
30
– – ﹤0.01% 900
2017
Q4 		$1K Hold
30
– – ﹤0.01% 887
2017
Q3 		$1K Hold
30
– – ﹤0.01% 896
2017
Q2 		$1K Buy
+30
New +$821 ﹤0.01% 730

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

San Francisco Sentry Investment Group's RIGL Position: Q2 2018 in Review

San Francisco Sentry Investment Group sold out of Rigel Pharmaceuticals (RIGL) in Q2 2018, closing a stake of 30 shares — an estimated $1K sold.

San Francisco Sentry Investment Group first reported a position in RIGL in Q2 2017 and held it in 4 quarters. The position peaked at $1K in Q1 2018. 131 funds tracked by Wall St. Rank hold RIGL as of Q2 2018.

  • San Francisco Sentry Investment Group reported no remaining Rigel Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 30 Rigel Pharmaceuticals shares in Q2 2018, an estimated $1K.
  • San Francisco Sentry Investment Group first reported a position in Rigel Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • San Francisco Sentry Investment Group's Rigel Pharmaceuticals position peaked at $1K in Q1 2018.
  • 131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2018.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2018, filed 6 Aug 2018.